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Abstract
Objective: Vitamin D plays an important role in mineral turnover and bone remodeling and there 
are increasing data about its immunomodulatory potential in different rheumatologic disorders. 
Deficiency of vitamin D is frequent in patients with spondyloarthritis (SpA) and some data suggest 
its association with increased disease activity and structural damage. However, its exact role in the 
pathogenesis of SpA and its association with disease activity are still a matter of debate. 
Material and methods: A cross-sectional study of patients diagnosed with axial spondyloarthritis 
(axSpA) and peripheral spondyloarthritis (perSpA) according to Assessment of Spondyloarthritis 
International Society classification criteria was performed. The correlation between concentra-
tion of 25-hydroxyvitamin D – 25(OH)D – and disease activity scores (Bath Ankylosing Spondylitis 
Disease Activity Index – BASDAI, Ankylosing Spondylitis Disease Activity Score – ASDAS), inflamma-
tory markers (C-reactive protein – CRP, erythrocyte sedimentation rate – ESR) and clinical symptoms 
(arthritis, enthesitis, dactylitis) was performed.
Results: We included 40 patients with axSpA and 23 patients with perSpA. The mean concentra-
tion of 25(OH)D was 24.9 ng/ml (SD 12.49). Forty-seven (74.6%) patients had 25(OH)D below the 
recommended threshold (< 30 ng/ml). We found no statistically significant negative correlation be-
tween the level of 25(OH)D and disease activity of axSpA and perSpA in terms of clinical symptoms 
(arthritis, enthesitis, dactylitis), inflammatory markers (ESR, CRP) and disease activity scores 
(BASDAI, ASDAS). These results did not change after adjustment for supplementation of vitamin D 
and seasonal variation. 
Conclusions: Our data show no correlation between the concentration of 25(OH)D in the serum 
and disease activity in two subgroups of SpA. However, this does not exclude the potential role of 
vitamin D in pathogenesis of SpA. Further studies are required to evaluate the optimal range of 
25(OH)D serum concentration in axSpA and perSpA patients with its possible immunomodulatory 
potential and influence on disease activity.
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Introduction
Deficiency of vitamin D is frequent in patients with 
spondyloarthritis (SpA) [1, 2] and some data suggest its 
association with increased disease activity and structur-
al damage [3, 4]. Apart from the endocrine role in bone 
metabolism by maintaining mineral homeostasis, vita-
min D3 can modulate both innate and adaptive immune 
responses. Notably, vitamin D modulates immune pro-
cesses inducing a shift from a pro-inflammatory T-helper 1 
(Th-1), Th-17 to an anti-inflammatory Th-2 and Treg pro-
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file [5] and possibly influences cytokine pathways in-
volved in SpA pathogenesis, especially IL-12/IL-23 and 
IL-17 [6].
Vitamin D3 has been shown to modulate matura-
tion and function of monocytes. As a part of the innate 
immune system monocytes seem to play an important 
role in the pathogenesis of SpA. Recently, a negative 
correlation between CD16 monocytes and peripheral 
arthritis in early SpA was observed [7]. In experimental 
studies vitamin D inhibited TNF and IL-1 secretion by 
monocytes [8]. Vitamin D up-regulated CD14 expression 
and down-regulated TLR2, TLR4 and TLR9 expression on 
human monocytes resulting in less IL-6 secretion [9]. 
However, this immunomodulatory effect requires a high 
1,25(OH)2D3 concentration in the immune cell microen-
vironment [10], probably difficult to achieve under refer-
ence concentrations in blood. Likewise, serum concen-
tration of 25(OH)D may not fully reflect the functional 
status of 1,25(OH)2D3 in the tissues given that proposed 
immune mechanisms are likely auto-/paracrine [5]. 
Several studies have shown dissimilar results for the 
relationship between serum 25(OH)D concentration and 
activity of SpA. Zhao et al. [3] found significantly higher 
Bath Ankylosing Spondylitis Disease Activity Index (BAS-
DAI), spinal pain visual analogue scale (VAS), erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) 
in axial spondyloarthritis (axSpA) patients deficient in 
vitamin 25(OH)D (< 30 nmol/l) as compared to non-de-
ficient patients. Also Hmamouchi et al. [4] reported high-
er BASDAI, Ankylosing Spondylitis Disease Activity Score 
(ASDAS) and radiological sacroiliitis score in early axSpA 
deficient for vitamin 25(OH)D (< 50 nmol/l). 
In a study by Erten et al. [1] vitamin D levels were 
inversely related with both ESR and CRP concentration 
in AS patients, but not in undifferentiated SpA. In this 
study 25(OH)D did not correlate with BASDAI in either 
group of patients. On the other hand, several reports did 
not confirm an association between vitamin D and ESR, 
CRP and BASDAI in axSpA [2, 11]. Also in a recent study 
of AS patients, Klingberg et al. [12] found no association 
between vitamin D deficiency (< 50 nmol/l) and disease 
activity, osteoproliferation, BMD, vertebral fractures or 
bowel inflammation. 
The aim of our study was to evaluate whether there 
would be a link between serum 25(OH)D concentration 
and disease activity in patients with axSpA and/or pe-
ripheral spondyloarthritis (perSpA).
Material and methods
Our study included consecutive patients with axSpA 
or perSpA according to Assessment of Spondyloarthritis 
International Society (ASAS) classification criteria. Some 
patients fulfilled New York criteria of ankylosing spondy-
litis (AS) and/or classification criteria for psoriatic arthri-
tis (PsA). During the visit a history of supplementation of 
vitamin D and blood samples for assessment of ESR, CRP 
and 25(OH)D level were taken and physical examination 
for presence of tender/swollen joints (TJC/SJC), enthesi-
tis and dactylitis was performed. The range of laboratory 
standards for vitamin 25(OH)D serum concentration in 
our laboratory is 30–80 ng/ml. Disease activity was as-
sessed by BASDAI) and ASDAS. 
Patients provided signed informed consent and the 
study protocol was approved by a local bioethics com-
mittee (no. 122.6120.44.2015).
The data management and analysis were performed 
with SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). 
Summary data are presented as means and standard 
deviations, or, in the case of non-normally distributed 
variables, as medians with inter-quartile ranges. We 
used the Spearman correlation to check for the rela-
tionships between analyzed variables. For the compar-
isons of values of studied variables across categories of 
vitamin D concentrations we employed non-parametric 
tests. 
Results
We included 40 patients with axSpA and 23 patients 
with perSpA. Overall, diagnoses included 29 patients 
with AS, 11 with non-radiographic axSpA, 12 with PsA, 
and 11 with perSpA. Patients were under 45 years, 22 
(34.9%) female and 41 (65.1%) male. Table I presents 
clinical and laboratory characteristics of the study group.
The mean concentration of 25(OH)D was 24.9 ng/ml 
(SD 12.49) and was comparable in axSpA vs. perSpA (24 
[SD 12.7] vs. 26.5 [SD 12.3], p = 0.45). Forty-seven (74.6%) 
patients had 25(OH)D below the recommended thresh-
old (< 30 ng/ml). We found no statistically significant 
negative correlation between the level of 25(OH)D and 
disease activity of axSpA and perSpA in terms of clinical 
symptoms (arthritis, enthesitis, dactylitis), inflammatory 
markers (ESR, CRP) and disease activity scores (BASDAI, 
ASDAS). We found no association between level of vita-
min D and the intensity of therapy (nonsteroidal anti- 
inflammatory drugs vs. conventional/biologic disease 
modifying drugs). We found a positive correlation be-
tween level of vitamin D and ESR in axSpA (Table II).
Spondyloarthritis subgroups analysis of patients 
with low 25(OH)D concentration (≤ 20 ng/ml) compared 
to higher 25(OH)D concentration (> 20 ng/ml) also 
showed no difference in ESR (7.5 vs. 12), CRP (1.94 vs. 
2.98 mg/l), BASDAI (2.35 vs. 3.3) or ASDAS (1.55 vs. 1.91). 
These results did not change after adjustment for sup-
plementation of vitamin D and seasonal variation. 
390 Zofia Guła, Anna Kopczyńska, Karolina Hańska, et al.
Reumatologia 2018; 56/6
Discussion
In our study we did not find a significant association 
between serum 25(OH)D concentration and activity of 
SpA. These results are in line with several previous stud-
ies that showed no direct link between serum concen-
tration of vitamin D and ESR, CRP, BASDAI and structural 
damage (osteoproliferation and osteoporosis) [2, 11, 12]. 
However, this does not exclude the potential role of vita-
min D in pathophysiology of SpA. First, the range of nor-
mal concentrations of vitamin D in serum may be much 
lower than expected to modulate inflammatory process-
es. Studies showing effects of vitamin D upon immuno-
logic cells were performed in vitro where the concentra-
tion of vitamin D was much greater than those measured 
in vivo [13]. Achieving such high levels of vitamin D in 
humans is linked with a significant risk of hypercalcemia. 
New agents such as selective VDR agonists, e.g. paricalci-
tol (19-nor-1,25-hydroxy-vitamin D2), may be of interest in 
inhibition of the inflammatory process without disturb-
ing calcium/phosphorus metabolism [10], but it must be 
confirmed in clinical trials. Second, serum concentration 
of 25(OH)D may not reflect the concentration of its active 
metabolite, 1,25(OH)2D3 in the inflammatory microenvi-
ronment. Possibly, not only serum vitamin D concentra-
tion, but local production of 1,25(OH)2D3 by macrophages, 
dendritic cells and T lymphocytes [13, 14] is pivotal in the 
auto and paracrine immunomodulatory effect.
In our analyses we found a positive correlation be-
tween level of vitamin D and ESR in axSpA. This finding 
is difficult to explain in the clinical context and must be 
confirmed by other observations.
Our results are contrary to data from other studies 
that reported a significant association between vita-
min D and activity of SpA as well as structural damage 
[1, 3, 4]. However, differences in the study population and 
in the definition of vitamin deficiency do not allow direct 
comparison of these results. We also cannot exclude sig-
Table I. Clinical and laboratory characteristics of studied group
Characteristic axSpA (n = 40) perSpA (n = 23) p
TJC ≥ 1 (%) 17.5 78.3 < 0.0001
SJC ≥ 1 (%) 12.5 69.6 < 0.0001
Enthesitis ≥ 1 (%) 2.5 43.5 < 0.0001
Dactylitis ≥ 1 (%) 0 13 0.02
ESR median (5–95 percentile) 8 (2–46) 12 (5–32) 0.39
CRP median (5–95 percentile) 1.3 (0–27.5) 3 (0–23) 0.54
BASDAI median (5–95 percentile) 2.4 (0.6–7) 3.8 (0.4–9) 0.16
ASDAS median (5–95 percentile) 1.7 (0.5–4.2) 2.1 (0.1–4.4) 0.5
Duration of symptoms, mean (±SD) months 7.9 (7.4) 5.6 (6) NS
axSpA – axial spondyloarthritis; perSpA – peripheral spondyloarthritis; TJC – tender joints count; SJC – swollen joints count; ESR – erythro- 
cyte sedimentation rate; CRP – C-reactive protein; BASDAI – Bath Ankylosing Spondylitis Disease Activity Index; ASDAS – Ankylosing 
Spondylitis Disease Activity Score; NS – not significant
Table II. Correlation between vitamin D concentration and disease activity
Characteristic axSpA perSpA
r p r p
TCJ –0.5 0.75 –0.2 0.94
SJC 0.12 0.46 0 1
Enthesitis –0.24 0.13 –0.1 0.65
Dactylitis – – –0.13 0.55
ESR 0.45 0.005 –0.02 0.94
CRP 0.26 0.11 –0.09 0.69
BASDAI 0.14 0.38 –0.38 0.08
ASDAS 0.14 0.38 –0.35 0.1
axSpA – axial spondyloarthritis; perSpA – peripheral spondyloarthritis; TJC – tender joints count; SJC – swollen joints count; ESR – erythro- 
cyte sedimentation rate; CRP – C-reactive protein; BASDAI – Bath Ankylosing Spondylitis Disease Activity Index; ASDAS – Ankylosing 
Spondylitis Disease Activity Score
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nificant bias due to the geographic latitude of the study 
centers. The strength of our study is that our patients 
were young, with relatively short duration of signs and 
symptoms and relatively good physical function, which 
exclude the impact of immobilization on vitamin D sta-
tus. We also performed adjustment for seasonal varia-
tion and supplementation of vitamin D, which did not 
show any significant differences.
Conclusions
To summarize, although achieving the recommend-
ed concentration of vitamin 25(OH)D is necessary due to 
its important role in bone metabolism, it still cannot be 
considered as a therapeutic option for inflammatory pro-
cesses in SpA. It is a matter of debate what the optimal 
concentration of 25(OH)D in serum is, that would have 
immunomodulatory potential, without posing a risk of 
hypercalcemia. In order to elucidate the relationship 
between serum vitamin D deficiency and SpA activity, 
randomized placebo-controlled trials are required.
The authors declare no conflict of interest.
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